/FHTX
FHTX Stock - Foghorn Therapeutics Inc.
Healthcare|BiotechnologyNASDAQ
$5.24+4.80%
+$0.24 (+4.80%) • Dec 19
66
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.82
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+119.5%upside
Target: $11.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for FHTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$5.19 – $5.29
TARGET (TP)$11.50
STOP LOSS$4.82
RISK/REWARD1:14.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta3.04
52W High$6.79
52W Low$2.94
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $22.60M | $34.16M | $19.23M | $1.32M | $430,000 |
| Gross Profit | $22.60M | $34.16M | $19.23M | $1.32M | $-57,285,000 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | -13322.1% |
| Operating Income | $-102,683,000 | $-107,906,000 | $-117,137,000 | $-100,734,000 | $-68,531,000 |
| Net Income | $-86,620,000 | $-98,426,000 | $-108,882,000 | $-101,320,000 | $-68,800,000 |
| Net Margin | -383.2% | -288.2% | -566.3% | -7681.6% | -16000.0% |
| EPS | $-1.58 | $-2.34 | $-2.62 | $-2.78 | $-1.90 |
Company Overview
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
9
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
9 Bullish0 Neutral/Bearish
Price Targets
$13
Average Target
↑ 154.5% Upside
Now
$9
Low
$13
Average
$20
High
Based on 9 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 18th 2025 | BTIG Research | Initiation | Buy | $11 |
| November 7th 2025 | Guggenheim | Initiation | Buy | $12 |
| September 17th 2025 | B. Riley Securities | Resumed | Buy | $10 |
| April 23rd 2025 | Citizens JMP | Initiation | Mkt Outperform | $9 |
| January 30th 2025 | B. Riley Securities | Initiation | Buy | $10 |
| September 3rd 2024 | Jefferies | Initiation | Buy | $18 |
| August 19th 2024 | Evercore ISI | Initiation | Outperform | $20 |
| March 28th 2023 | BofA Securities | Initiation | Buy | $10 |
| January 5th 2023 | BMO Capital Markets | Initiation | Outperform | $20 |
Earnings History & Surprises
FHTXBeat Rate
44%
Last 18 quarters
Avg Surprise
+3.4%
EPS vs Estimate
Beats / Misses
8/8
2 met exactly
Latest EPS
$-0.25
Q4 2025
EPS Surprise History
Q1 24
+27.8%
$-0.57vs$-0.79
Q2 24
-7.3%
$-0.59vs$-0.55
Q3 24
+25.0%
$-0.45vs$-0.60
Q4 24
+26.2%
$-0.31vs$-0.42
Q1 25
+30.2%
$-0.30vs$-0.43
Q2 25
0.0%
$-0.30vs$-0.30
Q3 25
+9.7%
$-0.28vs$-0.31
Q4 25
+19.4%
$-0.25vs$-0.31
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q1 2026 | Mar 5, 2026 | $-0.30 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.31 | $-0.25 | +19.4% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $-0.31 | $-0.28 | +9.7% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $-0.30 | $-0.30 | 0.0% | = MET |
Q1 2025 | Mar 6, 2025 | $-0.43 | $-0.30 | +30.2% | ✓ BEAT |
Q4 2024 | Nov 4, 2024 | $-0.42 | $-0.31 | +26.2% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.60 | $-0.45 | +25.0% | ✓ BEAT |
Q2 2024 | May 6, 2024 | $-0.55 | $-0.59 | -7.3% | ✗ MISS |
Q1 2024 | Mar 7, 2024 | $-0.79 | $-0.57 | +27.8% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $-0.72 | $-0.34 | +52.8% | ✓ BEAT |
Q3 2023 | Aug 4, 2023 | $-0.73 | $-0.70 | +4.1% | ✓ BEAT |
Q2 2023 | May 8, 2023 | $-0.68 | $-0.73 | -7.4% | ✗ MISS |
Q1 2023 | Mar 9, 2023 | $-0.59 | $-0.69 | -16.9% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-0.60 | $-0.62 | -3.3% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | $-0.53 | $-0.66 | -24.5% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-0.40 | $-0.65 | -62.5% | ✗ MISS |
Q1 2022 | Mar 10, 2022 | $-0.74 | $-0.77 | -4.1% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.66 | $-0.71 | -7.6% | ✗ MISS |
Q3 2021 | Aug 10, 2021 | $-0.63 | $-0.63 | 0.0% | = MET |
Latest News
Foghorn Therapeutics shares are trading higher after BTIG initiated coverage on the stock with a Buy rating and announced a $11 price target.
📈 PositiveBenzinga•Dec 18, 2025, 06:13 PM
BTIG Initiates Coverage On Foghorn Therapeutics with Buy Rating, Announces Price Target of $11
📈 PositiveBenzinga•Dec 18, 2025, 12:19 PM
Stifel Initiates Coverage On Foghorn Therapeutics with Buy Rating, Announces Price Target of $12
📈 PositiveBenzinga•Dec 4, 2025, 04:56 PM•Also:
Foghorn Therapeutics Named Jeff Sacher As Treasurer And Interim CFO
➖ NeutralBenzinga•Dec 4, 2025, 12:07 PM
Guggenheim Initiates Coverage On Foghorn Therapeutics with Buy Rating, Announces Price Target of $12
📈 PositiveBenzinga•Nov 7, 2025, 04:28 PM
Foghorn Therapeutics shares are trading higher after the company reported better-than-expected Q3 financial results.
📈 PositiveBenzinga•Nov 5, 2025, 05:23 PM
Foghorn Therapeutics Q3 EPS $(0.25) Beats $(0.30) Estimate, Sales $8.153M Beat $6.197M Estimate
📈 PositiveBenzinga•Nov 5, 2025, 12:14 PM
Foghorn Therapeutics To Present Updates For Selective ARID1B, Selective CBP, And Selective EP300 Degrader Programs, During Foghorn-Hosted Virtual Investor Event
➖ NeutralBenzinga•Oct 30, 2025, 11:37 AM
Foghorn Therapeutics Unveils Significant ARID1B Degrader Advances, Plans Virtual Investor Event For Pipeline Updates
📈 PositiveBenzinga•Oct 16, 2025, 11:04 AM
Frequently Asked Questions about FHTX
What is FHTX's current stock price?
Foghorn Therapeutics Inc. (FHTX) is currently trading at $5.24 per share. The stock has moved +4.80% today.
What is the analyst price target for FHTX?
The average analyst price target for FHTX is $11.50, based on 1 analyst.
What sector is Foghorn Therapeutics Inc. in?
Foghorn Therapeutics Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is FHTX's market cap?
Foghorn Therapeutics Inc. has a market capitalization of $0.30 billion, making it a small-cap company.
Does FHTX pay dividends?
No, Foghorn Therapeutics Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARCT
Arcturus Therapeutics Holdings Inc.
$6.53
Mkt Cap: $0.2B
ASMB
Assembly Biosciences, Inc.
$35.26
Mkt Cap: $0.3B
ENTA
Enanta Pharmaceuticals, Inc.
$15.39
Mkt Cap: $0.3B
HUMA
Humacyte, Inc.
$1.11
Mkt Cap: $0.2B
IMRX
Immuneering Corporation
$5.65
Mkt Cap: $0.2B
PYXS
Pyxis Oncology, Inc.
$1.27
Mkt Cap: $0.1B
SGMT
Sagimet Biosciences Inc.
$6.28
Mkt Cap: $0.2B
TRDA
Entrada Therapeutics, Inc.
$10.98
Mkt Cap: $0.4B
VNDA
Vanda Pharmaceuticals Inc.
$6.75
Mkt Cap: $0.4B
ZURA
Zura Bio Limited
$4.27
Mkt Cap: $0.3B
Explore stocks similar to FHTX for comparison